K H Au1, Roger K C Ngan2, Alice W Y Ng3, Darren M C Poon4, W T Ng5, K T Yuen6, Victor H F Lee7, Stewart Y Tung3, Anthony T C Chan8, Henry C K Sze5, Ashley C K Cheng6, Anne W M Lee7, Dora L W Kwong9, Anthony H P Tam10. 1. Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China. Electronic address: akhz01@ha.org.hk. 2. Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China. 3. Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China. 4. Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China. 5. Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China. 6. Department of Oncology, Princess Margaret Hospital, Hong Kong, China. 7. Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Clinical Oncology Center, The University of Hong Kong - Shenzhen Hospital, China. 8. State Key Laboratory of Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China. 9. Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 10. Hong Kong Cancer Registry, Hospital Authority, Hong Kong, China.
Abstract
PURPOSE: To evaluate treatment outcomes, failure patterns and late toxicities in patients with nasopharyngeal carcinoma (NPC) treated by intensity modulated radiotherapy (IMRT) in 6 public hospitals in Hong Kong over a 10-year period from 2001 to 2010. MATERIAL AND METHODS: Eligible patients were identified through the Hong Kong Cancer Registry data base. Clinical information was retrieved and verified by oncologists working in the individual centers. Treatment details, survival outcomes and late toxicities were analyzed. RESULTS: A total of 3328 patients were recruited. The median follow-up time was 80.2 months. The 8-year actuarial overall survival (OS), local failure-free survival (LFFS), regional failure-free survival (RFFS), distant failure free survival (DFFS), progression-free survival (PFS) for the whole group was 68.5%, 85.8%, 91.5%, 81.5% and 62.6% respectively. Male gender, older age, advanced T and N stage were adverse prognostic factors for OS, DFFS and PFS, whereas use of chemotherapy in form of concurrent chemo-irradiation (CRT), neoadjuvant + CRT, or CRT + adjuvant chemotherapy were favorable prognostic factors for OS and PFS. The local control was adversely affected by advanced T stage. N stage remained as the single adverse prognostic factor for regional control. Distant metastasis was the commonest site of failure. CONCLUSION: IMRT is an effective treatment for NPC with excellent overall loco-regional control. Distant metastasis is the major site of failure. Concurrent chemotherapy with cisplatin has an established role in NPC patients treated by IMRT.
PURPOSE: To evaluate treatment outcomes, failure patterns and late toxicities in patients with nasopharyngeal carcinoma (NPC) treated by intensity modulated radiotherapy (IMRT) in 6 public hospitals in Hong Kong over a 10-year period from 2001 to 2010. MATERIAL AND METHODS: Eligible patients were identified through the Hong Kong Cancer Registry data base. Clinical information was retrieved and verified by oncologists working in the individual centers. Treatment details, survival outcomes and late toxicities were analyzed. RESULTS: A total of 3328 patients were recruited. The median follow-up time was 80.2 months. The 8-year actuarial overall survival (OS), local failure-free survival (LFFS), regional failure-free survival (RFFS), distant failure free survival (DFFS), progression-free survival (PFS) for the whole group was 68.5%, 85.8%, 91.5%, 81.5% and 62.6% respectively. Male gender, older age, advanced T and N stage were adverse prognostic factors for OS, DFFS and PFS, whereas use of chemotherapy in form of concurrent chemo-irradiation (CRT), neoadjuvant + CRT, or CRT + adjuvant chemotherapy were favorable prognostic factors for OS and PFS. The local control was adversely affected by advanced T stage. N stage remained as the single adverse prognostic factor for regional control. Distant metastasis was the commonest site of failure. CONCLUSION: IMRT is an effective treatment for NPC with excellent overall loco-regional control. Distant metastasis is the major site of failure. Concurrent chemotherapy with cisplatin has an established role in NPCpatients treated by IMRT.
Authors: Kenneth C W Wong; Edwin P Hui; Kwok-Wai Lo; Wai Kei Jacky Lam; David Johnson; Lili Li; Qian Tao; Kwan Chee Allen Chan; Ka-Fai To; Ann D King; Brigette B Y Ma; Anthony T C Chan Journal: Nat Rev Clin Oncol Date: 2021-06-30 Impact factor: 66.675
Authors: Louise Soo Yee Tan; Benjamin Wong; Nagaraja Rao Gangodu; Andrea Zhe Ern Lee; Anthony Kian Fong Liou; Kwok Seng Loh; Hao Li; Ming Yann Lim; Andres M Salazar; Chwee Ming Lim Journal: Oncoimmunology Date: 2018-08-27 Impact factor: 8.110
Authors: Richard Du; Victor H Lee; Hui Yuan; Ka-On Lam; Herbert H Pang; Yu Chen; Edmund Y Lam; Pek-Lan Khong; Anne W Lee; Dora L Kwong; Varut Vardhanabhuti Journal: Radiol Artif Intell Date: 2019-07-10